Molecular Partners AG (OTCMKTS:MLLCF) Sees Large Drop in Short Interest

Molecular Partners AG (OTCMKTS:MLLCF) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totalling 59,300 shares, a drop of 46.7% from the August 15th total of 111,300 shares. Based on an average trading volume of 800 shares, the short-interest ratio is presently 74.1 days.

Molecular Partners stock traded up $0.27 during mid-day trading on Friday, hitting $19.83. 195 shares of the company’s stock were exchanged, compared to its average volume of 3,587. Molecular Partners has a 1-year low of $16.00 and a 1-year high of $33.00. The stock has a 50 day moving average of $19.69 and a two-hundred day moving average of $22.45.

About Molecular Partners

Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma.

See Also: Initial Coin Offering (ICO)

Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.